Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-25
2006-04-25
Kim, Vickie (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S253030, C514S321000, C514S649000, C514S651000
Reexamination Certificate
active
07034036
ABSTRACT:
The present invention relates to inhibitors of drug transporters of the ABC protein superfamily, particularly transporters present at the blood brain barrier. ABC transporter inhibitors identified according to the invention increase brain concentrations of CNS-active agents. Such inhibitors increase the influx into the brain and/or reduce the efflux from the brain of such CNS-active agents.
REFERENCES:
patent: 4774230 (1988-09-01), Tuttle et al.
patent: 4873076 (1989-10-01), Fishman et al.
patent: 5512593 (1996-04-01), Dante
patent: 5580876 (1996-12-01), Crain et al.
patent: 5767125 (1998-06-01), Crain et al.
patent: 5817665 (1998-10-01), Dante
patent: 5945510 (1999-08-01), Fasano
patent: 5958962 (1999-09-01), Cook
patent: 6034091 (2000-03-01), Dante
patent: 6120806 (2000-09-01), Whitmire
patent: 6153621 (2000-11-01), Hamann
patent: 6228863 (2001-05-01), Palermo et al.
patent: 6271240 (2001-08-01), Simon
patent: 6277384 (2001-08-01), Kaiko et al.
patent: 6284765 (2001-09-01), Caffrey
patent: 6323236 (2001-11-01), McElroy
patent: 6622036 (2003-09-01), Suffin
patent: 2002/0044968 (2002-04-01), van Lengerich
patent: 2003/0148941 (2003-08-01), Crain et al.
Bostöm, Emma, et al., “Oxycodone Pharmacokinetics and Pharmacodynamics in the Rat in the Presence of the P-Glycoprotein Inhibitor PSC833,” Journal of Pharmaceutical Sciences, vol. 94, No. May 2005 (1060-66).
Zhen-Li Liu, et al., “Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblasted leukemia MOLT-4 cells,”Journal of Controlled Release,78:43-54 (2002).
Hiroyuki Kushhara, et al., “Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney,”Journal of Controlled Release,78:43-54 (2002).
Editorial, “Membrane Transporters,”European Journal of Pharmaceutical Sciences,21:1 (2004).
Haiyung Sun, et al. “Drug efflux transporters in the CNS,”Advanced Drug Delivery Reviews,55:83-105 (2003).
Richard B. Kim, “Pharmacogenetics of CYP enzymes and drug transporters: remarkable recent advances,”Advanced Drug Delivery Reviews,54:1241-1242 (2002).
Tetsuya Terasaki, et al., “The Blood-brain barrier efflux transporters as a detoxifying system for the brain,”Advanced Drug Delivery Reviews,36:195-209 (1999).
Akira Tsuji, et al., “Carrier-mediated or specialized transport of drugs across the blood-brain barrier,”Advanced Drug Delivery Reviews,36:277-290 (1999).
Massimo Rizzi, et al., “Limbic Seizures Induce P-Glycoprotein in Rodent Brain: Functional Implications for Pharmacoresistance,”The Journal of Neuroscience,22(14):5833-5839 (Jul. 15, 2002).
Astrid A. Ruefli, et al., “HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance,”Blood,vol. 95, No. 7, 2378-2385 (Apr. 1, 2000).
Mark J. Smyth, et al., “The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of casepase-dependent apoptosis,”Proc. Natl. Acad. Sci. USA,vol. 95:7024-7029 (Jun. 1998).
Miki Susanto, et al., “Can the Enhanced Renal Clearance of Antibodies in Cystic Fibrosis Patients be Explained by P-Glycoprotein Transport?,”Pharmaceutical Research,vol. 19, No. 4, 457-462 (Apr. 2002).
Seong Hoon Jang, et al., “Kinetics of P-Glycoprotein-Mediated Efflux of Paclitaxel,”The Journal of Pharmacology and Experimental Therapeutics,vol. 298, No. 3, 1236-1242 (2001).
Ricky W. Johnstone, et al., “P-Glycoprotein Does Not Protect Cells against Cytolysis Induced by Pore-forming Proteins,”The Journal of Biological Chemistry,vol. 276, No. 20, 16667-16673 (May 18, 2001).
Ricky W. Johnstone, et al., “A Role for P-Glycoprotein in Regulating Cell Death,”Leukemia and Lymphoma,vol. 38(1-2), 1-11 (2000).
Ricky W. Johnstone, et al., “P-Glycoprotein Protects Leukemia Cells Against Caspase-Dependent, but not Caspase-Independent, Cell Death,”Blood,vol. 93, No. 3, 1075-1085 (Feb. 1, 1999).
Richard B. Kim, “Drugs As P-Glycoprotein Substrates, Inhibitors, and Inducers,”Drug Metabolism Reviews,34(1&2), 47-54 (2002).
Pamela L. Golden, et al., “Brain Microvascular P-Glycoprotein and a Revised Model of Multidrug Resistance in Brain,”Cellular and Molecular Neurobiology,vol. 20, No. 2, 165-181 (2000).
Hirofumi Hamada, et al., “Characterization of the ATPase Activity of the Mr170,000 to 180,000 Membrane Glycoprotein (P-Glycoprotein) Associated with Multidrug Resistance in K562/ADM Cells,”Cancer Research,48:4926-4932 (Sep. 1, 1988).
Donna S. Cox, et al., “Influence of multidrug resistance (MDR) proteins at the blood-brain barrier on the transporter distribution of enaminone anticonvulsants,”J. Pharm. Sci.,vol. 90, No. 10, pp. 1540-1552.
A. H. Dantzig, et al., “Considerations in the design and development of transport inhibitors as adjuncts to drug,”Advanced Drug Delivery Reviews,vol. 55, No. 1, pages 133-150 (2003).
A. H. Dantzig, et al., “Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (mrpl) orthologs and several ATP-binding cassette (ABC transporters),”Biochemical Pharmacology,vol. 67, No. 6, pp. 1111-1121 (2004).
T.R. Slouch, “Progress in understanding the structure-activity relationships of p-glycoprotein,”Advanced Drug Delivery Reviews,vol. 54, No. 3, pp. 315-328 (2002).
A.H. Schinkel, “Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview,”Advanced Drug Delivery Reviews,vol. 55, No. 1, pp. 3-29 (2003).
Pamela L. Golden, et al., “Blood-Brain Barrier Efflux Transport,”Journal of Pharmaceutical Sciences,vol. 92, No. 9, 1739-1753 (Sep. 2003).
Kim Vickie
McAndrews Held & Malloy Ltd.
Pain Therapeutics, Inc.
LandOfFree
Inhibitors of ABC drug transporters at the blood-brain barrier does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of ABC drug transporters at the blood-brain barrier, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of ABC drug transporters at the blood-brain barrier will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3565006